Compounded semaglutide isn't proven safe or unsafe as a category. It carries every risk on the semaglutide label, plus risks that come from how it's made and dosed. Compounded semaglutide skips FDA approval: no one at the FDA judges whether it is safe, whether it works, or how well it was made before a pharmacy sends it out [1]. Whether it works at all is a separate question, covered in does compounded semaglutide work.
Semaglutide's own risks come with every version
Start with the drug itself. Wegovy's label carries a boxed warning: semaglutide causes thyroid C-cell tumors in rodents, and it's unknown whether it does in people [3]. The label's warnings section lists these risks, in its own words:
- Risk of Thyroid C-Cell Tumors
- Acute Pancreatitis
- Acute Gallbladder Disease
- Hypoglycemia
- Acute Kidney Injury Due to Volume Depletion
- Severe Gastrointestinal Adverse Reactions
- Hypersensitivity Reactions
- Diabetic Retinopathy Complications in Patients with Type 2 Diabetes
- Heart Rate Increase
- Pulmonary Aspiration During General Anesthesia or Deep Sedation
The most common side effects are digestive. The label lists nausea, diarrhea, vomiting, constipation and abdominal pain first among reactions seen in at least 5% of patients [3]. One change worth knowing: the label dropped its suicidal behavior and ideation warning in February 2026. A compounded product shares all of these risks. It's meant to be the same molecule.
What FDA has flagged about compounded versions
FDA's GLP-1 page, current as of October 1, 2026, lists problems that are specific to compounded products [1]. As of May 31, 2026, the agency had received 990 adverse-event reports associated with compounded semaglutide. It adds that many look like the side effects of the approved drug, and that the true count is likely higher because pharmacies that aren't outsourcing facilities don't have to report to FDA. Treat 990 as a floor.
| Risk | Source | Applies to the brand too? | What you can do |
|---|---|---|---|
| Nausea, vomiting, diarrhea, constipation | Wegovy label [3] | Yes | Tell your prescriber if symptoms persist; fluid loss can strain the kidneys |
| Acute pancreatitis | Wegovy label [3] | Yes | Severe belly pain that may spread to the back: stop and call your prescriber |
| Gallbladder disease | Wegovy label [3] | Yes | Call your prescriber if gallbladder trouble is suspected |
| Thyroid C-cell tumors (boxed warning) | Wegovy label [3] | Yes | Don't take it with a personal or family history of MTC or MEN 2; report a neck lump or hoarseness |
| Dosing errors | FDA [1]; case reports [6] | Mainly vials | Have the pharmacist or prescriber go over your dose before the first one |
| Doses beyond the label's schedule | FDA [1] | Compounded | Ask how your plan compares with the label's dose steps |
| Salt forms (sodium, acetate) | FDA [1] | No | Check that the label says semaglutide, with no salt named |
| Fraudulent pharmacy labels | FDA [1] | Counterfeit pens exist too | Look the pharmacy up with your state board or FDA's outsourcing-facility list |
| Shipments that arrive warm | FDA [1] | Yes | Don't use it; contact the pharmacy or program |
| Contamination in multi-dose vials after 28 days | FDA [1] | Vials only | Discard the vial 28 days after first use |
| Suppliers not licensed for sterile compounding | Secret-shopper study [4] | No | Ask which pharmacy compounds it, then check its license |
Brand rows describe the Wegovy label's warnings. Compounded products carry them too, plus the rows FDA added for compounded versions.
Dosing errors have sent some people to the hospital
FDA received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products. These dosing errors resulted from patients measuring and self-administering incorrect doses of the drug, and in some cases, health care professionals miscalculating doses of the drug.[1]
Brand pens are built to deliver set doses. Compounded semaglutide may come in a multi-dose vial instead, which lacks the pen's safety features [6]. In a poison-center case series, two of three people who got compounded semaglutide from pharmacies or a spa took ten times their intended dose. All three had nausea, vomiting and abdominal pain, most of it lasting days. A published case report describes a woman who needed a breathing tube for four days after an accidental ten-fold first dose [7].
FDA has also received reports tied to doses "beyond what is in the FDA-approved drug label": bigger single doses, more frequent doses, or faster increases [1]. Before your first dose, have the pharmacist or prescriber go over exactly what you'll take and how it compares with the label's schedule.
Salt forms: read the active ingredient on your label
Some compounders have sold semaglutide sodium or semaglutide acetate. FDA says these salts "are different active ingredients than are used in the approved drugs", that it has no information on whether they behave the same, and that it is "not aware of any lawful basis for their use in compounding" [1]. If your label names a salt, ask the pharmacy why before you use it.
Quality depends on which pharmacy made it
Pharmacies compounding under section 503A are overseen mainly by state boards of pharmacy. Outsourcing facilities registered under section 503B are overseen by FDA and must meet current good manufacturing practice rules, which 503A pharmacies don't [2]. FDA also warns that people who buy compounded drugs online "may not know the identity of the compounder that produced the drug" [2].
Supply chains vary widely. In a 2025 secret-shopper study of 75 clinics and medical spas in two states, researchers traced 23 supplying pharmacies. Four of the 21 checked weren't licensed for sterile compounding. Three of 22 had faced state disciplinary action [4]. Separately, a lab study by Novo Nordisk scientists found compounded samples differed from the brand in impurities and strength after light exposure; it measured chemistry, not patient harm [5].
Who shouldn't take semaglutide at all
The label rules semaglutide out for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and for anyone who has had a serious allergic reaction to semaglutide [3]. Pregnancy is the other firm line. The label says "Weight loss offers no benefit to a pregnant patient and may cause fetal harm," and advises stopping at least 2 months before a planned pregnancy because the drug lingers in the body. The same rules apply to a compounded product.
How to check a compounded semaglutide program
You can't test a vial, but you can test the program. Some programs name their compounding pharmacy on their own sites, including Embody, Midi Health and MEDGm, so you can look the pharmacy up yourself. The compounded semaglutide scores show which programs do, and how to get compounded semaglutide walks through sign-up.
- Find the compounding pharmacy's name, then confirm its license with your state board, or check FDA's outsourcing-facility list.
- Read the active ingredient: semaglutide, with no sodium or acetate salt named.
- Expect a screening by a licensed prescriber before anything ships, and a way to reach a clinician afterward.
- Look for cold-chain packaging, and refuse a package that arrives warm.
- Note the date you first use a multi-dose vial; FDA says to discard it 28 days later.
- Walk away from claims that the product is "the same as" an FDA-approved drug, or prices that seem too good to be true.
Those last red flags come straight from FDA's list for telehealth buyers [1]. Storage limits are covered in how long compounded semaglutide lasts in the fridge. Whether compounded semaglutide will stay legal to sell is a separate question, tracked in will compounded semaglutide be banned. For the basics, see the compounded semaglutide guide.
Reporting a problem helps FDA see it
Tell your prescriber first if you have a side effect or a quality problem. Then contact the pharmacy or program that sent the drug. FDA asks patients to report adverse events and quality problems through MedWatch, online or by fax at 1-800-FDA-0178 [8]. Because 503A pharmacies don't have to report adverse events to FDA, your report may be the only one it gets.